Table 4.
Predictors of development of venous thromboembolism in patients with cancer.
| Variable | Colon HR (95% CI) | Breast HR (95% CI) | Glioma HR (95% CI) | Ovarian HR (95% CI) |
|---|---|---|---|---|
| Gender | ||||
| Female vs male | 1.0 (0.9–1.1) | – | 0.8 (0.7–0.9)§ | – |
| Age (versus <45 years) | ||||
| 45–64 years | 1.1 (0.9–1.3) | 1.4 (1.2–1.8)§ | 2.4 (1.9–3.0)§ | 1.9 (1.3–2.6)§ |
| 65–74 years | 1.2 (1.0–1.5)* | 1.9 (1.5–2.4)§ | 2.6 (2.0–3.4)§ | 1.8 (1.3–2.6)§ |
| >75 years | 1.0 (0.9–1.2) | 2.0 (1.6–2.6)§ | 1.8 (1.4–2.5)§ | 1.5 (1.0–2.2)* |
| Race (vs Caucasian) | ||||
| Black | 0.9 (0.8–1.1) | 1.3 (1.0–1.5)* | 0.8 (0.6–1.2) | 1.3 (1.0–1.8) |
| Hispanic | 0.8 (0.7–1.0)§ | 0.9 (0.8–1.1) | 0.8 (0.6–1.0) | 0.9 (0.7–1.1) |
| Asian-American | 0.4 (0.3–0.5)§ | 0.3 (0.2–0.4)§ | 0.4 (0.2–0.6)§ | 0.8 (0.5–1.1) |
| Number of chronic co-morbidities† (vs 0) | ||||
| 1 | 1.2.(1.0–1.4)* | 1.9 (1.6–2.2)§ | 2.3 (1.9–2.8)§ | 2.1 (1.7–2.6)§ |
| 2 | 1.5 (1.3–1.8)§ | 2.3 (1.9–2.7)§ | 2.8 (2.2–3.5)§ | 2.6 (2.0–3.3)§ |
| 3 | 2.0 (1.7–2.3)§ | 2.9 (2.4–3.5)§ | 3.5 (2.8–4.3)§ | 3.9 (3.1–4.8)§ |
| Stage (vs local-stage cancer) | ||||
| Regional | 2.1 (1.8–2.4) § | 2.1 (1.8–2.3)§ | N/A | 1.7 (1.1–2.6)* |
| Metastatic | 3.2 (2.8–3.8) § | 6.3 (5.3–7.5)§ | N/A | 3.0 (2.1–4.2)§ |
| Major cancer surgery | ||||
| Yes vs No | 0.4 (0.3–0.4) § | 0.6 (0.5–0.7) § | 1.7 (1.3–2.3) § | 0.7 (0.6–0.8) § |
HR, hazard ratio; CI, confidence interval.
Follow-up time for ovary, breast and glioma = 2 years; follow-up time for colon = 1 year.
†
Examples: heart failure, chronic liver disease, chronic lung disease, paralysis, rheumatic disease
*
P<0.05.
§
P<0.001.